Stiff-Person Syndrome: A Comprehensive Review of a Rare Disease with Emphasis on Pathophysiology, Clinical Features, Diagnostic Challenges and Therapeutic Advances.
5 affiliations
- 1Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda, Punjab, India.
- 2Department of Microbiology, Government Medical College, Handwara, Jammu and Kashmir, India.
- 3Kashmir Institute of Medical Sciences and Technology, Lawaypora, Jammu and Kashmir, India.
- 4Department of Radio Diagnosis, Government Medical College Srinagar, Jammu and Kashmir, India.
- 5Baba Moniji Maharaj Group of Nursing College, Lehra Mohabbat, Bathinda, Punjab, India.
Abstract
Stiff-person syndrome (SPS) is an rare autoimmune neurological disorder that is associated with progressive axial and proximal muscle rigidity, stimulus-sensitive painful spasms, and significant functional disability. The disorder is commonly associated with high-titer antibodies against glutamic acid decarboxylase-65 (GAD65), leading to impaired gamma-aminobutyric acid (GABA)-mediated inhibitory neurotransmission, resulting in persistent motor neuron hyperexcitability. Despite the conventional classification of SPS as a motor disorder, the condition commonly occurs with neuropsychiatric symptoms, such as anxiety, phobic behaviors, and depression that often occur before the motor symptoms and can significantly increase diagnostic error or misdiagnosis. This review summarizes existing knowledge of the epidemiology, immunopathophysiology, clinical spectrum, diagnostic dilemmas, and treatment developments in SPS. This review also discusses the expanded concept of the stiff-person spectrum disorders that include classic SPS, stiff-limb syndrome, SPS-plus forms, and progressive encephalomyelitis with rigidity and myoclonus. Complexity in the diagnosis is associated with clinical heterogeneity, the variability of assays in anti-GAD65 testing, seronegative manifestations, and overlap of functional and psychiatric disorders, which highlights the role of electrophysiological validation and intrathecal immune scale. Management includes symptomatic treatment aimed at increasing GABAergic inhibition combined with disease-modifying immunotherapies, specifically intravenous immunoglobulin and B-cell-directed therapies in cases of refractory treatment. Despite progress in mechanistic comprehension and treatment, SPS has not been adequately diagnosed and is not substantiated by sufficient data on high-quality clinical trials. There is a need for early identification, proper diagnostic stewardship, and multidisciplinary care to enhance functional outcomes and quality of life. Future studies should address standard diagnostic criteria, phenotyping based on biomarkers, and specific immunotherapeutics.
Related
- Cardiorenal Syndrome: Pathophysiology, Management, and the Challenge of Therapeutic Inertia
- Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome
- OA06 Catastrophic anti-phospholipid syndrome presenting as stroke in a young male: diagnostic and therapeutic challenges in a resource-limited setting
- Kallmann syndrome revealed by primary amenorrhea: Phenotypic variability and diagnostic challenges—A report of three cases
- Case Report: Late-onset BK polyomavirus-associated nephropathy with encephalitis, antibody-mediated rejection, and atypical hemolytic uremic syndrome: a rare overlap causing allograft dysfunction, therapeutic challenges, and multidisciplinary management
BibTeX
@article{dar2026stiffperson,
title = {{Stiff-Person Syndrome: A Comprehensive Review of a Rare Disease with Emphasis on Pathophysiology, Clinical Features, Diagnostic Challenges and Therapeutic Advances.}},
author = {Mudasir Manzoor Dar and Ansar Ahmad Paray and Shaheena and Irshad Ahmad Najar and Wajid Gulzar and Mir Shabnum Javid and Tawfeeq Ahmad and Suraya Sikandar},
journal = {The Yale journal of biology and medicine},
year = {2026},
month = jun,
doi = {10.59249/adke4751},
url = {https://europepmc.org/article/MED/42852333},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Stiff-Person Syndrome: A Comprehensive Review of a Rare Disease with Emphasis on Pathophysiology, Clinical Features, Diagnostic Challenges and Therapeutic Advances.
AU - Mudasir Manzoor Dar
AU - Ansar Ahmad Paray
AU - Shaheena
AU - Irshad Ahmad Najar
AU - Wajid Gulzar
AU - Mir Shabnum Javid
AU - Tawfeeq Ahmad
AU - Suraya Sikandar
PY - 2026
DA - 2026/06/01
JO - The Yale journal of biology and medicine
DO - 10.59249/adke4751
UR - https://europepmc.org/article/MED/42852333
AB - Stiff-person syndrome (SPS) is an rare autoimmune neurological disorder that is associated with progressive axial and proximal muscle rigidity, stimulus-sensitive painful spasms, and significant functional disability. The disorder is commonly associated with high-titer antibodies against glutamic acid decarboxylase-65 (GAD65), leading to impaired gamma-aminobutyric acid (GABA)-mediated inhibitory neurotransmission, resulting in persistent motor neuron hyperexcitability. Despite the conventional classification of SPS as a motor disorder, the condition commonly occurs with neuropsychiatric symptoms, such as anxiety, phobic behaviors, and depression that often occur before the motor symptoms and can significantly increase diagnostic error or misdiagnosis. This review summarizes existing knowledge of the epidemiology, immunopathophysiology, clinical spectrum, diagnostic dilemmas, and treatment developments in SPS. This review also discusses the expanded concept of the stiff-person spectrum disorders that include classic SPS, stiff-limb syndrome, SPS-plus forms, and progressive encephalomyelitis with rigidity and myoclonus. Complexity in the diagnosis is associated with clinical heterogeneity, the variability of assays in anti-GAD65 testing, seronegative manifestations, and overlap of functional and psychiatric disorders, which highlights the role of electrophysiological validation and intrathecal immune scale. Management includes symptomatic treatment aimed at increasing GABAergic inhibition combined with disease-modifying immunotherapies, specifically intravenous immunoglobulin and B-cell-directed therapies in cases of refractory treatment. Despite progress in mechanistic comprehension and treatment, SPS has not been adequately diagnosed and is not substantiated by sufficient data on high-quality clinical trials. There is a need for early identification, proper diagnostic stewardship, and multidisciplinary care to enhance functional outcomes and quality of life. Future studies should address standard diagnostic criteria, phenotyping based on biomarkers, and specific immunotherapeutics.
SN - 0044-0086
SN - 1551-4056
ER -